血清胸腺激酶1、CA125监测在中晚期卵巢癌患者化疗中的临床意义  

Clinical Significance of Serum Thymidine Kinase 1 and CA125 Monitoring in Chemotherapy of Advanced Ovarian Cancer Patients

作　　者：李珂[1] 安宁[2] Li Ke;An Ning(Department of Clinical Medical Laboratory,Chengdu Third People’s Hospital,Chengdu,Sichuan 610031;Department of Oncology,Sichuan Academy of Medical Sciences&Sichuan Provincial People′s Hospital,Chengdu,Sichuan 610072,China)

机构地区：[1]成都市第三人民医院临床医学检验部,四川成都610031 [2]四川省医学科学院·四川省人民医院肿瘤科,四川成都610072

出　　处：《四川医学》2020年第8期835-838,共4页Sichuan Medical Journal

摘　　要：目的检测中晚期卵巢癌患者化疗前后血清中胸腺激酶1(S-TK1)水平、CA125水平的意义。方法分别对42例中晚期卵巢癌患者化疗前后及30例健康体检者的血清S-TK1水平、CA125水平进行检测。结果观察组血清S-TK1水平、CA125水平均明显高于健康组(P<0.05);观察组化疗后无疾病进展的卵巢癌患者血清S-TK1水平、CA125水平较化疗前呈下降趋势(P<0.05);有疾病进展的卵巢癌患者血清S-TK1水平、CA125水平较化疗前呈上升趋势(P<0.05);两项指标联合检测,其敏感性和特异性高于单项检测(P<0.05);42例中晚期卵巢癌患者化疗前临床病理特征组间的血清S-TK1水平、CA125水平未见明显差异(P>0.05)。结论监测血清S-TK1水平、CA125水平在评估中晚期卵巢癌患者疗效中具有临床应用价值。Objective To observe the significance of detecting serum thymidine kinase 1( S-TK1) and CA125 in advanced ovarian cancer. Methods Serum S-TK1 and CA125 of42 patients with advanced ovarian cancer before and after chemotherapy and 30 healthysubjects were tested.Results S-TK1 and CA125 in observation group were significantly higher than thosein healthygroup( P<0.05). S-TK1 and CA125 without disease progression after chemotherapy in observation group showed a downward trend compared with those before chemotherapy( P<0.05).S-TK1 and CA125 in advanced ovarian cancershowed an upward trend compared with those before chemotherapy( P<0.05).The combined detection of two markers had higher sensitivity and specificity than single detection( P<0.05).There were no significant differences in S-TK1 and CA125 between clinic-pathological characteristics groups of 42 advanced ovarian cancerpatients before chemotherapy( P>0.05). Conclusion Monitoring S-TK1 and CA125 may have significance in the chemotherapy efficacy evaluation for advanced ovarian cancer.

关 键 词：血清胸腺激酶1 CA125 卵巢癌 

分 类 号：R737.31[医药卫生—肿瘤]